Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:PSTX Poseida Therapeutics (PSTX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestSustainabilityTrendsBuy This Stock About Poseida Therapeutics Stock (NASDAQ:PSTX) 30 days 90 days 365 days Advanced Chart Remove Ads Get Poseida Therapeutics alerts:Sign Up Key Stats Today's Range$9.50▼$9.5050-Day Range$9.33▼$9.6052-Week Range$1.87▼$9.67VolumeN/AAverage Volume861,342 shsMarket Capitalization$928.85 millionP/E RatioN/ADividend YieldN/APrice Target$9.50Consensus RatingHold Company OverviewPoseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications. It is also involved in the development of P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, colorectal, lung, ovarian, pancreatic, and renal cancers; P-PSMA-ALLO1, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in preclinical development for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC); and P-PSMA-101, an allogeneic CAR-T product candidate under Phase 1 clinical trial for treating mCRPC. In addition, the company engages in the development of P-FVIII-101, a clinical stage liver-directed gene therapy for the in vivo treatment of hemophilia A; P-OTC-101, a clinical stage liver-directed gene therapy for the in vivo treatment of ornithine transcarbamylase deficiency; and P-PAH-101, a clinical stage liver-directed gene therapy for the in vivo treatment of phenylketonuria. It has a research collaboration and license agreement with F. Hoffmann-La Roche Ltd, and Hoffmann-La Roche Inc. The company was incorporated in 2014 and is headquartered in San Diego, California.Read More… Remove Ads Poseida Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks9th Percentile Overall ScorePSTX MarketRank™: Poseida Therapeutics scored higher than 9% of companies evaluated by MarketBeat, and ranked 909th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.0 / 5Analyst RatingHold Consensus RatingPoseida Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 5 hold ratings, and no sell ratings.Amount of Analyst CoveragePoseida Therapeutics has received no research coverage in the past 90 days.Read more about Poseida Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Poseida Therapeutics are expected to decrease in the coming year, from ($1.02) to ($1.80) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Poseida Therapeutics is -15.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Poseida Therapeutics is -15.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPoseida Therapeutics has a P/B Ratio of 8.80. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for PSTX. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPoseida Therapeutics does not currently pay a dividend.Dividend GrowthPoseida Therapeutics does not have a long track record of dividend growth. Sustainability and ESG4.6 / 5Environmental Score-0.93 Short InterestThere is no current short interest data available for PSTX. News and Social Media0.6 / 5News SentimentN/A Search Interest4 people have searched for PSTX on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Poseida Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.90% of the stock of Poseida Therapeutics is held by insiders.Percentage Held by Institutions46.87% of the stock of Poseida Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Poseida Therapeutics' insider trading history. Receive PSTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Poseida Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address PSTX Stock News HeadlinesRoche Finalizes Poseida Acquisition: This Cell Therapy Deal Feels Like A Win/WinJanuary 9, 2025 | seekingalpha.comRoche set to finalise $1.5bn Poseida Therapeutics takeoverJanuary 8, 2025 | proactiveinvestors.comWhile Markets Slide, These "Genesis Cog" Trades Are Up Double-DigitsWhile most investors are struggling in today's volatile market, a small group of traders are quietly booking consistent gains. Just last week, our Genesis Cog subscribers captured an 11.51% gain shorting JEF, another 8.57% on CAKE, and 4.78% on RJF—all while the broader indexes continued their downward trend.March 25, 2025 | Theo Trade (Ad)Roche to complete acquisition of U.S. biopharma company PoseidaJanuary 8, 2025 | reuters.comCautious Hold Rating on Poseida Therapeutics Amid Promising Data and Strategic UncertaintiesDecember 10, 2024 | markets.businessinsider.comPoseida Therapeutics Highlights Positive Interim Phase 1 Results for P-BCMA-ALLO1 and Preclinical Data for Dual CAR-T P-CD19CD20-ALLO1 at the 66th American Society of Hematology (ASH) Annual MeetingDecember 9, 2024 | prnewswire.comPoseida Therapeutics downgraded to Neutral from Overweight at Piper SandlerDecember 2, 2024 | markets.businessinsider.comRoche’s Acquisition Offer Leads to Hold Rating for Poseida Therapeutics Amid Promising Pipeline and Financial UncertaintiesDecember 2, 2024 | markets.businessinsider.comSee More Headlines PSTX Stock Analysis - Frequently Asked Questions How were Poseida Therapeutics' earnings last quarter? Poseida Therapeutics, Inc. (NASDAQ:PSTX) issued its quarterly earnings data on Thursday, November, 7th. The company reported $0.21 EPS for the quarter, topping analysts' consensus estimates of ($0.42) by $0.63. The firm had revenue of $71.75 million for the quarter, compared to analyst estimates of $15 million. Poseida Therapeutics had a negative net margin of 40.28% and a negative trailing twelve-month return on equity of 72.26%. When did Poseida Therapeutics IPO? Poseida Therapeutics (PSTX) raised $150 million in an IPO on Friday, July 10th 2020. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. BofA Securities, Piper Sandler and William Blair acted as the underwriters for the IPO. Who are Poseida Therapeutics' major shareholders? Top institutional investors of Poseida Therapeutics include FMR LLC (10.24%), Pentwater Capital Management LP (8.82%), Nomura Holdings Inc. (5.23%) and Vanguard Group Inc. (3.92%). Insiders that own company stock include Life Sciences Holdings L Malin, Eric Ostertag and Mark J Gergen. View institutional ownership trends. What other stocks do shareholders of Poseida Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Poseida Therapeutics investors own include Invesco QQQ (QQQ), SPDR S&P 500 ETF Trust (SPY), SPDR Dow Jones Industrial Average ETF Trust (DIA), NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META) and Broadcom (AVGO). Company Calendar Last Earnings11/07/2024Today3/25/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PSTX CIK1661460 Webwww.poseida.com Phone858-779-3100FaxN/AEmployees260Year FoundedN/APrice Target and Rating Average Stock Price Target$9.50 High Stock Price Target$10.00 Low Stock Price Target$9.00 Potential Upside/Downside0.0%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($0.63) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-123,430,000.00 Net Margins-40.28% Pretax Margin-40.25% Return on Equity-72.26% Return on Assets-21.53% Debt Debt-to-Equity Ratio0.68 Current Ratio3.20 Quick Ratio3.20 Sales & Book Value Annual Sales$150.86 million Price / Sales6.16 Cash FlowN/A Price / Cash FlowN/A Book Value$1.08 per share Price / Book8.80Miscellaneous Outstanding Shares97,774,000Free Float94,939,000Market Cap$928.85 million OptionableOptionable Beta1.63 A Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free Report This page (NASDAQ:PSTX) was last updated on 3/25/2025 by MarketBeat.com Staff From Our PartnersYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Poseida Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Poseida Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.